Resources
Materials for you and your practice
Download helpful materials to keep information nearby about the basics of clonoSEQ, specimen requirements, and more.
![](/wp-content/uploads/2024/04/img_4.1_Resources_HCP_brochure_thumbnail.jpg)
clonoSEQ HCP Brochure
Everything you need to know about clonoSEQ, including how it benefits patients, in one resource.
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.